Scarica l'app Stockscreener
75.04
5.01%
-3.96
Dopo l'orario di chiusura:
76.54
1.50
+2.00%
Precedente Chiudi:
$79.00
Aprire:
$79.44
Volume 24 ore:
280.85K
Relative Volume:
0.73
Capitalizzazione di mercato:
$1.09B
Reddito:
$1.80M
Utile/perdita netta:
$1.76B
Rapporto P/E:
0.6323
EPS:
118.674
Flusso di cassa netto:
$-149.23M
1 W Prestazione:
-6.45%
1M Prestazione:
-8.77%
6M Prestazione:
+376.75%
1 anno Prestazione:
+392.07%
Intervallo 1D:
$74.46
$82.34
Intervallo di 1 settimana:
$74.46
$82.34
Portata 52W:
$10.80
$94.56
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Confronta INBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
75.04 | 1.15B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Sees Large Decline in Short Interest - MarketBeat
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts - Insider Monkey
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 7.2% – Here’s Why - Defense World
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 7.2%Should You Buy? - MarketBeat
Why Inhibrx's Recent Strength May Not Be Built to LastInhibrx Biosciences (NASDAQ:INBX) - Benzinga
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 7.9%Here's Why - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 1-Year HighHere's Why - MarketBeat
Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - 富途牛牛
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Inhibrx Biosciences Earnings Notes - Trefis
Why Inhibrx Biosciences Inc. stock could rally in 2025July 2025 Market Mood & Fast Gain Stock Tips - Улправда
Is Inhibrx Biosciences Inc. stock trading at a premium valuation2025 Dividend Review & Low Risk Investment Opportunities - bolumsonucanavari.com
Buyout Rumor: How Inhibrx Biosciences Inc. stock benefits from tech adoptionWall Street Watch & High Yield Equity Trading Tips - ulpravda.ru
Can Inhibrx Biosciences Inc. stock deliver surprise earnings beatJuly 2025 Update & Accurate Trade Setup Notifications - DonanımHaber
Can Inhibrx Biosciences Inc. stock withstand economic slowdownWeekly Trend Recap & Short-Term Trading Alerts - DonanımHaber
How Inhibrx Biosciences Inc. stock benefits from tech adoptionJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Will Inhibrx Biosciences Inc. stock deliver consistent dividends2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates - Yahoo Finance
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates - Sahm
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - The Malaysian Reserve
Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures - Investing.com Canada
Inhibrx Biosciences, Inc provides progress updates on the Inbrx-106 program and the expansion cohorts of the Ozekibart (Inbrx-109) program - marketscreener.com
Inhibrx Biosciences Announced An Update On The INBRX-106 Phase 2/3 Clinical Trial In Combination With Keytruda; Inhibrx Expects To Complete Enrollment In The Phase 2 Portion Of The Trial During The First Quarter Of 2026 - Sahm
Inhibrx Biosciences Provides Updates on Clinical Trials - TradingView — Track All Markets
[8-K] Inhibrx Biosciences, Inc. Reports Material Event | INBX SEC FilingForm 8-K - Stock Titan
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 6.6%Here's Why - MarketBeat
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
EDGAR Filing Documents for 0002007919-25-000093 - SEC.gov
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX - MarketBeat
Why Is INBX Stock Rising Today? - MSN
Franklin Resources Inc. Makes New $316,000 Investment in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences advances sarcoma research with ozekibart trial results - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5%Here's What Happened - MarketBeat
Inhibrx Biosciences, Inc. $INBX Shares Acquired by Kennedy Capital Management LLC - MarketBeat
With Inhibrx Biosciences Stock Surging, Have You Considered The Downside? - Trefis
Inhibrx Biosciences (NASDAQ:INBX) Trading 6.8% HigherWhat's Next? - MarketBeat
Is Inhibrx Biosciences Inc. stock a buy on dipsDollar Strength & Real-Time Market Trend Scan - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD By Investing.com - Investing.com Nigeria
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week HighHere's Why - MarketBeat
Why Inhibrx Biosciences Inc. stock is favored by top institutions2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD - Investing.com
Avoiding Lag: Real-Time Signals in (INBX) Movement - news.stocktradersdaily.com
Inhibrx Biosciences boosts MSTS 2025 with platinum sponsorship - Traders Union
Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Earnings Report: How sustainable is Inhibrx Biosciences Inc. stock dividend payoutBond Market & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Inhibrx Biosciences unveils preclinical progress in glioblastoma treatment - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Sets New 1-Year HighHere's Why - MarketBeat
Inhibrx Biosciences stock hits all-time high at 87.4 USD By Investing.com - Investing.com Nigeria
Inhibrx Biosciences stock hits all-time high at 87.4 USD - Investing.com
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):